Effect of vitamin B6 on treatment of ulcerative colitis

Evaluation of vitamin B6 efficacy in clinical and laboratory manifestation of patients with Ulcerative colitis

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017063034820N1

Enrollment

Registered

2017-08-29

Start date

2017-09-06

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis. ulcerative colitis

Interventions

Intervention 1: Control group: patients with ulcerative colitis (number=30) that receive routine treatment with placebo (40 mg/day). Intervention 2: Intervention group: patients with ulcerative coliti

Placebo

Treatment - Drugs

Control group: patients with ulcerative colitis (number=30) that receive routine treatment with placebo (40 mg/day).

Intervention group: patients with ulcerative colitis (number=30) that receive routine treatment with vitamin B6 (40 mg/day).

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with ulcerative colitis confirmed by clinical diagnosis, pathology, and previous results of colonoscopy; before this, have not used from vitamin B6 and other vitamin B derivatives for ulcerative colitis; patients in any stage and with any intensity are candidate for participating in the study. Exclusion criteria: persons with parkinsonism that use Levodopa, simultaneously (because of interfere with vitamin B6 and Levodopa); patient unwillingness for continue to study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Daily defecation. Timepoint: duration of the study. Method of measurement: times.;Admission. Timepoint: 0 & 6th months of the study. Method of measurement: times.;Mesalazine drug. Timepoint: 0 & 6th months of the study. Method of measurement: dosage.	—

Secondary

Measure	Time frame
ESR. Timepoint: 0 & 6 months of the study. Method of measurement: Blood test.;CRP. Timepoint: 0 & 6 months of the study. Method of measurement: Blood test.;Plasma homocysteine. Timepoint: 0 & 6 months of the study. Method of measurement: Blood test.;Stooll Calprotectin. Timepoint: 0 & 6 months of the study. Method of measurement: stool exam.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFateme Panahande

Ahwaz Jundishapour University of Medical Sciences

Fateme.b.dr@gmail.com+98 916 674 1582

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026